FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:1342-1349 November 5, 1992 Number 19 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. In 1984, the Eastern Cooperative Oncology Group began a randomized controlled clinical trial of patients with advanced (stage III or IV) diffuse mixed or diffuse large-cell lymphoma to determine whether complete-remission rates, survival, and toxicity differed when patients were treated with a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as compared with a regimen containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD). METHODS. From July 1984 through January 1988, 392 patients were enrolled, 325 of whom (83 percent) were eligible for the analysis and capable of being evaluated. The extent of disease was defined according to standard staging techniques, including bilateral bone-core biopsies in 88 percent of patients. Randomization was stratified according to age (< 60 or > or = 60 years), performance status (0, 1, or other), stage (III or IV), and histologic presentation (diffuse mixed or diffuse large-cell lymphoma). RESULTS. After a median follow-up of four years, there were no significant differences in rates of complete remission, time to treatment failure, disease-free survival, or overall survival in the patients treated with CHOP as compared with those treated with m-BACOD. However, there was more severe and life-threatening pulmonary, infectious, and hematologic toxicity associated with the m-BACOD regimen. In an attempt to measure the importance of dose intensity in the 325 patients who could be analyzed, we retrospectively calculated dose intensity (measured in milligrams per square meter of body-surface area per week) and normalized dose intensity (defined as a percentage of the prescribed dose) for all drugs. The median normalized dose intensity for both cyclophosphamide and doxorubicin was found to be greater in the patients treated with CHOP than in those treated with m-BACOD. CONCLUSIONS. For patients with stage III or IV diffuse mixed or diffuse large-cell lymphoma, CHOP is superior to m-BACOD, but the role of dose intensity is not yet clear.

Source Information

Northwestern University Medical School, Department of Medicine, Chicago, IL 60611.

This article has been cited by other articles:

• Mohammad, R. M., Goustin, A. S., Aboukameel, A., Chen, B., Banerjee, S., Wang, G., Nikolovska-Coleska, Z., Wang, S., Al-Katib, A. (2007). Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. Clin. Cancer Res. 13: 2226-2235 [Abstract] [Full Text]  
• Verdonck, L. F., Notenboom, A., de Jong, D. D., MacKenzie, M. A., Verhoef, G. E. G., Kramer, M. H. H., Ossenkoppele, G. J., Doorduijn, J. K., Sonneveld, P., van Imhoff, G. W. (2007). Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 109: 2759-2766 [Abstract] [Full Text]  
• Habermann, T. M. (2007). Antibody Therapy in Aggressive Lymphomas. ASH Education Book 2007: 257-264 [Abstract] [Full Text]  
• Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., Horning, S. J. (2006). Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. JCO 24: 3121-3127 [Abstract] [Full Text]  
• Compton, C. (2006). The cancer and leukemia group B pathology committee at 50.. Clin. Cancer Res. 12: 3617s-3621s [Abstract] [Full Text]  
• Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J.-B., Vaccher, E., Carbone, A., Coiffier, B., Chichino, G., Bosly, A., Tirelli, U., Gisselbrecht, C., for the French-Italian cooperative group, (2006). AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107: 3832-3840 [Abstract] [Full Text]  
• Gobbi, P. G., Broglia, C., Valentino, F., Mammi, C., Lombardo, M., Merli, F., Luminari, S., Polimeno, G., Riezzo, A., Lambelet, P., Rovati, A., Corazza, G. R., Federico, M. (2006). The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). Ann Oncol 17: 676-682 [Abstract] [Full Text]  
• Rizvi, M. A., Evens, A. M., Tallman, M. S., Nelson, B. P., Rosen, S. T. (2006). T-cell non-Hodgkin lymphoma. Blood 107: 1255-1264 [Abstract] [Full Text]  
• Olivieri, A., Santini, G., Patti, C., Chisesi, T., De Souza, C., Rubagotti, A., Aversa, S., Billio, A., Porcellini, A., Candela, M., Centurioni, R., Congiu, A. M., Brunori, M., Nati, S., Spriano, M., Vimercati, R., Marino, G., Contu, A., Tedeschi, L., Majolino, I., Crugnola, M., Sertoli, M. R. (2005). Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol 16: 1941-1948 [Abstract] [Full Text]  
• Sakane-Ishikawa, E., Nakatsuka, S.-i., Tomita, Y., Fujita, S., Nakamichi, I., Takakuwa, T., Sugiyama, H., Fukuhara, S., Hino, M., Kanamaru, A., Soma, T., Tsukaguchi, M., Igarashi, K., Kanakura, Y., Aozasa, K. (2005). Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group. JCO 23: 8012-8017 [Abstract] [Full Text]  
• Abramson, J. S., Shipp, M. A. (2005). Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106: 1164-1174 [Abstract] [Full Text]  
• Vose, J. M., Bierman, P. J., Enke, C., Hankins, J., Bociek, G., Lynch, J. C., Armitage, J. O. (2005). Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma. JCO 23: 461-467 [Abstract] [Full Text]  
• Mohammad, R. M., Wang, S., Aboukameel, A., Chen, B., Wu, X., Chen, J., Al-Katib, A. (2005). Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(-)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics 4: 13-21 [Abstract] [Full Text]  
• Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., Grillo-Lopez, A. J. (2004). Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. JCO 22: 4711-4716 [Abstract] [Full Text]  
• Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Furman, R., Schuster, M. W., Feldman, E. J., Ashe, M., Schuster, S. J., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., Gayko, U., Fields, S. Z., Cesano, A., Goldenberg, D. M. (2004). Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results. Clin. Cancer Res. 10: 5327-5334 [Abstract] [Full Text]  
• Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D. A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J., Moskowitz, C. H. (2004). Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103: 3684-3688 [Abstract] [Full Text]  
• Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., Aikawa, K., Tsushita, K., Hiraoka, A., Matsuno, Y., Nakamura, S., Mori, S., Ohashi, Y. (2004). Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15: 821-830 [Abstract] [Full Text]  
• Pless, M., Belhadj, K., Menssen, H. D., Kern, W., Coiffier, B., Wolf, J., Herrmann, R., Thiel, E., Bootle, D., Sklenar, I., Muller, C., Choi, L., Porter, C., Capdeville, R. (2004). Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma: Results from a Phase II Multicenter Study. Clin. Cancer Res. 10: 1299-1305 [Abstract] [Full Text]  
• Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T. J., Gisselbrecht, C., Reyes, F. (2003). Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102: 4284-4289 [Abstract] [Full Text]  
• Mohammad, R. M., Al-Katib, A., Aboukameel, A., Doerge, D. R., Sarkar, F., Kucuk, O. (2003). Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Molecular Cancer Therapeutics 2: 1361-1368 [Abstract] [Full Text]  
• Coiffier, B. (2003). Increasing Chemotherapy Intensity in Aggressive Lymphomas: A Renewal?. JCO 21: 2457-2459 [Full Text]  
• Martelli, M., Gherlinzoni, F., De Renzo, A., Zinzani, P. L., De Vivo, A., Cantonetti, M., Falini, B., Storti, S., Meloni, G., Rizzo, M., Molinari, A. L., Lauria, F., Moretti, L., Lauta, V. M., Mazza, P., Guardigni, L., Pescarmona, E., Pileri, S.A., Mandelli, F., Tura, S. (2003). Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial. JCO 21: 1255-1262 [Abstract] [Full Text]  
• Vose, J.M., Crump, M., Lazarus, H., Emmanouilides, C., Schenkein, D., Moore, J., Frankel, S., Flinn, I., Lovelace, W., Hackett, J., Liang, B.C. (2003). Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. JCO 21: 514-519 [Abstract] [Full Text]  
• Peterson, B. A., Petroni, G. R., Frizzera, G., Barcos, M., Bloomfield, C. D., Nissen, N. I., Hurd, D. D., Henderson, E. S., Sartiano, G. P., Johnson, J. L., Holland, J. F., Gottlieb, A. J. (2003). Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B. JCO 21: 5-15 [Abstract] [Full Text]  
• Balzarotti, M., Spina, M., Sarina, B., Magagnoli, M., Castagna, L., Milan, I., Ripa, C., Latteri, F., Bernardi, D., Bertuzzi, A., Nozza, A., Roncalli, M., Morenghi, E., Tirelli, U., Santoro, A. (2002). Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol 13: 1341-1346 [Abstract] [Full Text]  
• Itoh, K., Ohtsu, T., Fukuda, H., Sasaki, Y., Ogura, M., Morishima, Y., Chou, T., Aikawa, K., Uike, N., Mizorogi, F., Ohno, T., Ikeda, S., Sai, T., Taniwaki, M., Kawano, F., Niimi, M., Hotta, T., Shimoyama, M., Tobinai, K. (2002). Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 13: 1347-1355 [Abstract] [Full Text]  
• Kostakoglu, L., Coleman, M., Leonard, J. P., Kuji, I., Zoe, H., Goldsmith, S. J. (2002). PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin's Disease. JNM 43: 1018-1027 [Abstract] [Full Text]  
• Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., Gisselbrecht, C. (2002). CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. NEJM 346: 235-242 [Abstract] [Full Text]  
• Kouroukis, C. T., Browman, G. P., Esmail, R., Meyer, R. M. (2002). Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma: A Systematic Review. ANN INTERN MED 136: 144-152 [Abstract] [Full Text]  
• van Besien, K., Kelta, M., Bahaguna, P. (2001). Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management. JCO 19: 1855-1864 [Abstract] [Full Text]  
• Vose, J. M., Link, B. K., Grossbard, M. L., Czuczman, M., Grillo-Lopez, A., Gilman, P., Lowe, A., Kunkel, L. A., Fisher, R. I. (2001). Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. JCO 19: 389-397 [Abstract] [Full Text]  
• Mohammad, R. M., Wall, N. R., Dutcher, J. A., Al-Katib, A. M. (2000). The Addition of Bryostatin 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model. Clin. Cancer Res. 6: 4950-4956 [Abstract] [Full Text]  
• Moreno, A., Colon-Otero, G., Solberg, L. A. Jr. (2000). The Prednisone Dosage in the CHOP Chemotherapy Regimen for Non-Hodgkin's Lymphomas (NHL): Is There a Standard?. The Oncologist 5: 238-249 [Abstract] [Full Text]  
• Tilly, H., Mounier, N., Lederlin, P., Briere, J., Dupriez, B., Sebban, C., Bosly, A., Biron, P., Nouvel, C., Herbrecht, R., Bordessoule, D., Coiffier, B. (2000). Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study. JCO 18: 1309-1315 [Abstract] [Full Text]  
• Front, D., Bar-Shalom, R., Mor, M., Haim, N., Epelbaum, R., Frenkel, A., Gaitini, D., Kolodny, G. M., Israel, O. (2000). Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with 67Ga Scintigraphy1. Radiology 214: 253-257 [Abstract] [Full Text]  
• Gordon, L. I., Young, M., Weller, E., Habermann, T. M., Winter, J. N., Glick, J., Ghosh, C., Flynn, P., Cassileth, P. A. (1999). A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity. Blood 94: 3307-3314 [Abstract] [Full Text]  
• Groopman, J. E., Itri, L. M. (1999). Chemotherapy-Induced Anemia in Adults: Incidence and Treatment. JNCI J Natl Cancer Inst 91: 1616-1634 [Abstract] [Full Text]  
• Nicolaides, C., Dimou, S., Pavlidis, N. (1998). Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas. The Oncologist 3: 189-197 [Abstract] [Full Text]  
• Winter, J. N., Andersen, J., Reed, J. C., Krajewski, S., Variakojis, D., Bauer, K. D., Fisher, R. I., Gordon, L. I., Oken, M. M., Jiang, S., Jeffries, D., Domer, P. (1998). BCL-2 Expression Correlates With Lower Proliferative Activity in the Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study. Blood 91: 1391-1398 [Abstract] [Full Text]  
• Nademanee, A., Molina, A., O'Donnell, M. R., Dagis, A., Snyder, D. S., Parker, P., Stein, A., Smith, E., Planas, I., Kashyap, A., Spielberger, R., Fung, H., Wong, K.K., Somlo, G., Margolin, K., Chow, W., Sniecinski, I., Vora, N., Blume, K. G., Niland, J., Forman, S. J. (1997). Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group. Blood 90: 3844-3852 [Abstract] [Full Text]  
• Kaplan, L. D., Straus, D. J., Testa, M. A., Von Roenn, J., Dezube, B. J., Cooley, T. P., Herndier, B., Northfelt, D. W., Huang, J., Tulpule, A., Levine, A. M., The National Institute of Allergy and Infectious D, (1997). Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus Infection. NEJM 336: 1641-1648 [Abstract] [Full Text]  
• Engelhard, M., Brittinger, G., Huhn, D., Gerhartz, H. H., Meusers, P., Siegert, W., Thiel, E., Wilmanns, W., Aydemir, U., Bierwolf, S., Griesser, H., Tiemann, M., Lennert, K. (1997). Subclassification of Diffuse Large B-Cell Lymphomas According to the Kiel Classification: Distinction of Centroblastic and Immunoblastic Lymphomas Is a Significant Prognostic Risk Factor. Blood 89: 2291-2297 [Abstract] [Full Text]  
• Verdonck, L. F., van Putten, W. L.J., Hagenbeek, A., Schouten, H. C., Sonneveld, P., van Imhoff, G. W., Kluin-Nelemans, H. C., Raemaekers, J. M.M., van Oers, R. H.J., Haak, H. L., Schots, R., Dekker, A. W., de Gast, G. C., Lowenberg, B. (1995). Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin's Lymphoma. NEJM 332: 1045-1051 [Abstract] [Full Text]  
• Meyer, R. M., Quirt, I. C., Skillings, J. R., Cripps, M.C., Bramwell, V., Weinerman, B. H., Gospodarowicz, M. K., Burns, B. F., Sargeant, A. M., Shepherd, L. E., Zee, B., Hryniuk, W. M. (1993). Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma. NEJM 329: 1770-1776 [Abstract] [Full Text]  
• The International Non-Hodgkin's Lymphoma Prognosti, (1993). A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. NEJM 329: 987-994 [Abstract] [Full Text]  
• Longo, D. L., DeVita, V. T., Young, R. C., Salloum, E., Levin, M., Fisher, R. I. (1993). CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. NEJM 329: 580-582 [Full Text]  
• Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., Glenn, S. D., Wahl, R. L. (1993). Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody. NEJM 329: 459-465 [Abstract] [Full Text]  
• Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., Miller, T. P. (1993). Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma. NEJM 328: 1002-1006 [Abstract] [Full Text]  
• Armitage, J. O. (1993). Treatment of Non-Hodgkin's Lymphoma. NEJM 328: 1023-1030 [Full Text]  
• Hryniuk, W., Gordon, L. I., Harrington, D., Andersen, J. (1993). CHOP versus m-BACOD in Non-Hodgkin's Lymphoma. NEJM 328: 581-581 [Full Text]